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Abstract 
Around 2008 synthetic cannabinoids were found to be present in; and responsible for the psychoactive effects of 
herbal mixtures with names like ‘Spice’ or ‘K2’. In response to the increased popularity of these products, 
(inter)national organizations and governments started banning these cannabimimetics gradually. However, the 
lack of an uniform and international regulation makes it hard to control this issue.  
For the different types of synthetic cannabinoids the scientific knowledge in terms of pharmacokinetics and 
pharmacodynamics is limited. This also means that little is known on the health of users, both on short and long 
term.  
In the last years effort has been made to make detection of these products possible in different biological 
matrices. However, since the number of cannabimimetic compounds on the market appears to grow every 
month, both scientist and legislators run after a moving target. 
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INTRODUCTION 
 
 Starting from 2004, a new 
generation of psychoactive substances 
appeared on the market. These products, 
with brand names like ‘Spice’ or ‘K2’, are 
sold as herbal mixtures and are available in 
many European countries (1). Packed as 
‘natural herbal incense’ or ‘room 
odorizers’, these products can be traded 
legally in headshops and online stores 
(2,3). After smoking these mixtures, users 
reported cannabis-like effects on internet 
forums. These effects were first explained 
in 2008 by the detection of synthetic 
cannabinoids like JWH-018 as active 
ingredient (4) , although not mentioned on 
the package. 
 Throughout the years, more of 
these products were identified as additives 
in these packages of herbal material. As a 
response to the rising popularity of these 
compounds, several countries started 
monitoring and even banning these 
products (5). 
 The search for compounds with 
THC-like properties in the human body, 
i.e. synthetic cannabinoid receptor agonists 
or briefly cannabimimetics, started in the 
pharmaceutical industry. In a way to 
separate the wanted pain-relieving effects 
from the unwanted psychotropic effects, 
several categories of products were 
synthesized and subjected to SAR 
(structure activity relationship) tests. The 
academic and/or pharmaceutical origin of 
these compounds is often reflected in the 
name of the product. In the best known 
class of JWH-compounds, these initials 
stands for the name of the organic 
chemistry professor John W. Huffman, 
who first synthesized these products in the 
1990s. In a similar way AM (e.g. in AM-
630) refers to professor Alexandros 
Makriyannis from Northeastern University 
and HU (e.g. from HU-210) to Hebrew 
University. Also, the pharmaceutical 
industry realized the potential value of 
these products, leading to the synthesis of 
the CP-family (e.g. CP-47,497) by Pfizer 
and the WIN-group (e.g. WIN 55,212-2) 
by the former Sterling Winthrop 
Pharmaceuticals. 
 In general, it are lipid soluble, non-
polar molecules, containing 20 to 26 
carbon atoms (6). Based upon this 
chemical structure, synthetic cannabinoids 
can be divided into different classes (Table 
1) (1). 
• Classical cannabinoids: structurally 
related to THC from Cannabis sativa. 
• Non-classical cannabinoids: 
cyclohexylphenols or 3-arylcyclohexanols 
• Hybrid cannabinoids: structural 
combinations of both classical and non-
classical cannabinoids.  
• Aminoalkylindoles; 
o Naphthoylindoles 
o Phenylacetylindoles 
o Naphthylmethylindoles 
o Benzoylindoles 
• Eicosanoids: endocannabinoids and 
synthetic analogs 
• Others: diarylpyrazoles, naphthoyl-
pyrroles, etc. 
 It should be noted that, depending 
on the source, the classifications can vary. 
In the light of an internationally uniformed 
approach, referring to the 
(abovementioned) classification of a 
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leading institution as the United Nations 
Office on Drugs and Crime (UNODC) is 
recommended.
Classical cannabinoids 
e.g. THC, HU-210, AM906, … 
 
Non-classical cannabinoids 
e.g. CP-47,497-C8, CP-55,940, HU-308, … 
 
Hybrid cannabinoids 
e.g. AM-4030 
 
 
 
 
 
 
Naphthoylindoles 
e.g. JWH-018, JWH-073, JWH-122, JWH-
200, … 
 
Phenylacetylindoles 
e.g. JWH-250, RCS-8, JWH-203, … 
 
Naphthylmethylindoles 
e.g. JWH-175, JWH-184, JWH-185, … 
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Benzoylindoles 
e.g. AM-630, AM-2233, RCS-4, … 
 
Eicosanoids 
e.g. anandamide, methanandamide, … 
 
Others 
e.g. JWH-307, CRA-13, … 
 
Table 1. Classification of synthetic cannabinoids according to the UNODC (1), with some typical 
examples. The underlined compound is illustrated in the second column. 
 
ABUSE OF SYNTHETIC 
CANNABINOIDS 
 
 Packages of ‘Spice’ usually contain 
approximately 3g of herbal material and 
are often sold in head shops, gas stations or 
via internet shops. The price varies around 
€10/g, which is considered expensive 
compared to traditional cannabis (4). It is 
promised that the inhalation of the blends 
of psychoactive plants gives the user a 
similar experience as marijuana, only using 
legal alternatives. A survey in the US 
showed that ‘Spice’ products were 
primarily smoked, but also administration 
via vaporization, oral and rectal ingestion 
were reported (7). 
 Little is known on the exact 
composition and the properties of the used 
plants and in many cases the ingredients 
listed on the package do not cover the 
content either (8,9). The manufacturers of 
these blends make users believe the effects 
are caused by the mix of plant material 
used. However, research on the botanical 
material showed that most of the plant 
species do not have psychoactive 
properties and are therefore only used to 
dilute the added cannabimimetics (9). 
Moreover, the producers try to present 
their products as natural and safe in order 
to circumvent the marijuana policy of 
governments. The UNODC concluded that 
producers respond very fast to changes in 
legislations by making small modifications 
to the new products launched (1).  
 The success of this ‘legal-highs’ 
business is reflected in the increasing 
O
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number of web shops selling these 
products online. In 2009, the European 
Monitoring Centre for Drugs and Drugs 
addiction (EMCDDA) found 115 online 
shops offering psychoactive substances in 
Europe, in 48% of these ‘Spice’ products 
were offered. In a recent report mention is 
made of an increase to 314 online shops in 
2011 and 690 in January 2012 (10). 
Moreover, an investigation via Google® 
performed by the Belgian Monitoring 
Centre for Drugs and Drug Addiction 
(BMCDDA), showed that all new products 
reported in 2010 were already offered for 
sale online even before their existence was 
picked up by the Belgium Early Warning 
System for Drugs (BEWSD) (11). Also the 
list of products with names like ‘Spice 
gold’, ‘Yucatan Fire’ and ‘Lava Red’ 
continued to rise (8). Furthermore, recent 
investigation in Poland demonstrated that 
many herbal blends contained more than 
one psychoactive ingredient (12). 
 A survey of the member states of 
the European Union by the EMCDDA 
showed that in 2009, ‘Spice’ products were 
identified in 21 out of the 30 countries. At 
that time no products containing synthetic 
cannabinoids were found in Belgium. In 
2011 however, Belgian laboratories 
reported 11 synthetic cannabinoids to the 
European Early Warning System (EWS) 
and for the first time a complete laboratory 
capable of producing and packing synthetic 
cannabinoids was dismantled in Belgium. 
Similar facilities were reported in Ireland 
and the Netherlands and are the link 
between the producers – mainly located in 
China and India – and the customers in 
Europe. Since these substances can be 
produced cheaply, it is clear that these 
businesses are very lucrative (10). During 
the production process, the synthesized 
synthetic cannabinoids are distributed over 
the dried plant material. This is usually 
done by homogenization with 
cannabinoids in the crystalline form or by 
spraying the products dissolved in an 
organic solvent. However, recently also the 
starting materials are being sold as 
‘research chemicals’ via online shops or 
traders (13). 
 The rate at which a specific product 
is spreading, is also noteworthy. In Europe, 
JWH-018 was first reported by Austria in 
December 2008. Only in the first year after 
this, eight more neighboring countries 
confirmed this finding, followed by ten 
more in the next months. Similar 
developments were reported for other 
compounds like JWH-073 (13 countries), 
CP47, 497 (10 countries), JWH-122 (14 
countries), JWH-081 (10 countries) and 
AM-2201 (11 countries) (11). In 2011, 
already 23 new synthetic cannabimimetics 
were reported through the European Early 
Warning System (EWS), in 2012, another 
30 followed. With a current total of 84 
compounds (May 2013), the synthetic 
cannabinoid receptor agonists are, despite 
their recent introduction, already the 
largest drug family monitored by the 
EMCDDA (14). 
 An internet search learned that 
mostly young people - especially men - 
aged between 25 and 40 are using Spice-
like products. The reasons are various; 
ranging from previous cannabis users 
looking for a substitute over people in 
search of legal drugs to experimental users 
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seeking sensation (8). In 2008, German 
authorities found a strong increase in the 
interest for these products after a period of 
biased media attention in which their use 
as legal cannabis substitutes was 
announced. Once the presence of synthetic 
compounds was demonstrated and some of 
these products were banned, the opposite 
trend was observed, leaving only the users 
looking for a cannabis substitute to avoid 
positive testing (1). 
 Even in sport drug testing, the first 
cannabimimetics were reported in the 
statistics of the World Anti-Doping 
Agency (WADA). However, with only 3 
positive cases in 2011, the number remains 
small compared to the traditional THC 
abuse in sport competitions (n = 442 in 
2011) (15). 
 
LEGISLATION 
 
 Since synthetic cannabinoids are 
currently not controlled under the UN 
Drug control conventions, the legal status 
of these compounds depends on the drug 
laws of individual countries (1).  
 In Europe, the first actions by 
governments were taken in 2009. The first 
discovered compounds JWH-018, HU-210 
and CP47,479 and its homologues were 
included in national drug laws in Austria, 
Germany, France, Luxembourg, Sweden, 
Estonia, Poland, Hungary and the United 
Kingdom. A recent report on the evolution 
of the situation in Poland over the last few 
years, showed that both the compounds 
and the way of trading changed in response 
to the successive actions of the Polish 
government (12). As mentioned earlier, it 
is sufficient to make a small change in the 
drug structure to stay one step ahead of the 
legislator. Therefore, the UK and Ireland 
started using generic definitions to include 
products which will appear in the future 
(8). Recently, other European countries 
also adopted this strategy in substitution 
for the earlier used approach of individual 
listing of already identified synthetic 
cannabinoids (10). 
 In Belgium the first legislative 
actions were taken in 2011, by adding the 
first seven compounds to the list of 
prohibited psychotropic substances. In 
2013 six more cannabimimetics were listed 
(Table 2). Unfortunately, to this day, no 
generic definitions have come into force. 
 In the United States, the Synthetic 
Drug Abuse Prevention Act of 2012 placed 
cannabimimetic agents in Schedule I, 
making manufacturing, distributing, or 
possessing these products illegal. Besides 
this federal law, several states and even 
individual cities have taken additional 
measures to control ‘Spice’ abuse (16). 
 Since, similar to classical cannabis, 
the synthetic analogues are predominantly 
smoked, it is not inconceivable that passive 
inhalation of the smoke can result in 
positive testing. Once this was observed 
for cannabis (17), threshold concentrations 
were installed to distinguish active from 
passive use (18). However, up to now, this 
possibility has not been studied for the 
cannabimimetics currently flooding the 
market. 
 In general legislation, both within 
and outside Europe, is too diverse and 
therefore not efficient to tackle 
international issues as ‘legal highs’. 
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KB 2011-09-26/16, art. 1,011 
Effective date: 23/10/2011 
KB 2013-03-20/08, art. 1,012 
Effective date: 22/04/2013 
JWH-018 AM-694 
JWH-073 AM-2233 
JWH-250 WIN 48,098 
JWH-398 JWH-307 
CP-47,497 A-796,260 
HU-210 XLR-11 (5F-UR144) 
JWH-210  
Table 2. Synthetic cannabinoids present on the list of prohibited psychotropic substances in Belgium. 
 
PHARMACOKINETICS 
 
 Contrary to the classical THC for 
which the pharmacokinetics have been 
investigated (19,20), no such data are 
available for the synthetic analogues. 
As described in several reports on the 
experiences of ‘Spice’ users, the effect is 
quickly noticeable after smoking a few 
grams of herbal material (2,6,16). These 
observations are supported by a recent 
study on the quantification of JWH-018 in 
blood after smoking the incense ‘Smoke’ 
(21); the maximum concentrations were 
found 5 min post-smoking. This shows that 
after inhalation, the absorption via the 
lungs and the distribution over organs like 
the brain takes place in a few minutes (1). 
It was found that the measured maximum 
blood concentrations of JWH-018  were 
already decimated after 3h and the parent 
compound was detectable until 48h after 
administration (21). 
 Investigation of the metabolisation 
of cannabimimetics is not as 
straightforward as for pharmaceutical 
approved agents. Since there are little or no 
pharmacological data available for these 
compounds, human administration in order 
to perform excretion studies is ethically 
questionable. Therefore, most studies use 
models to reveal the metabolic pathways in 
the human body. In one of the most 
common approaches human liver 
microsomes are used to investigate the 
metabolisation in vitro (22–25), in the 
search for a more complete model with 
higher complexity also in vivo mice 
experiments are performed (26). In some 
cases, human urine samples are available 
from caught users (27–29) or conducted 
self-experiments (30).  
 In general, these compounds are 
excessively metabolized in the human 
body. In all metabolic studies on 
compounds of the aminoalkylindole family 
described up to now a similar series of 
modifications were found: single or 
multiple hydroxylations, carboxylation, 
dehydrogenation, dealkylation and 
dihydrodiol formation. From the data 
obtained using in vivo models or positive 
urine samples, is was found that these 
metabolites are mainly excreted as 
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glucuronide and/or sulphate conjugates in 
urine (26). Mainly the monohydroxylated 
(31) and carboxylated (28) metabolites are 
found in the highest quantities in urine. 
 
PHARMACODYNAMICS 
 
 Although the effects of Cannabis 
sativa and derivates are known for 
centuries, it was only in the last twenty 
years that the interactions in the human 
body were revealed (6,32). 
 Today, two cannabinoid receptors 
are described in the human body. Both 
CB1 and CB2 are G-protein coupled 
receptors with an important function in 
intercellular signaling. The CB1 receptor is 
distributed in the brain and the central 
nervous system, mainly expressed 
presynaptically, and decreases the release 
of neurotransmitters like dopamine (33). 
Activation of the CB1 receptor is 
responsible for the psychotropic effects 
assigned to cannabis use. 
 CB2 receptors are located in 
immune cells and interfere in the 
regulation of the inflammatory process 
(19). Therefore in the medical field, 
research has focused on receptor agonists 
selective for this CB2 receptor aiming for 
the therapeutic effects and hereby avoiding 
the psychotropic effects induced by the 
interaction with the CB1 receptor. 
 Next to endocannabinoids, plant 
derived and other exogenous cannabinoids 
act as agonists of both receptors with 
varying affinity. Classical cannabinoids 
like THC have comparable affinity for 
both receptors, about 40 nM, without a 
major selectivity for a particular receptor 
(34). As shown in Table 3, this is different 
for synthetic cannabinoids. The affinity of 
the most prevalent cannabimimetic 
compounds is significantly higher, 
especially towards the CB1 receptor. With 
this in mind, it can be expected that 
compounds with lower potency (i.e. lower 
affinity for the CB1 receptor) than classical 
THC will not be used in ‘Spice’-like 
products. Nevertheless JWH-015 was 
recently detected in a herbal blend in 
Latvia (1). 
 When using data on receptor 
affinities, one should be careful when 
using exact numbers. Indeed, depending on 
the used experimental set-up, variation in 
the values is possible (34). In short, the 
receptor affinity (Ki) is determined as the 
ability of the given compound to displace a 
potent radio labeled cannabinoid (usually 
tritiated CP-55,940 or tritiated WIN-
55,512-2) from their binding sites (35). For 
a potent cannabinoid, low concentrations 
will be sufficient to achieve this. Since this 
concentration (IC50) is proportional to the 
receptor affinity Ki, the more potent the 
cannabinoid, the lower Ki (Table 3). 
 
HEALTH RISKS 
 
 Although there are case reports 
describing the effects experienced 
immediately after the use of ‘Spice’ 
(2,3,16), little or no information is 
available on the long term effects or the 
consequences of regular use.  
 In 2009, Zimmermann et al. 
reported on a patient who showed 
symptoms of a physical withdrawal 
syndrome after using ‘Spice Gold’ on a
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Compound  Ki - CB1 (nM) Ki - CB2 (nM) 
HU-210 0.06 (34) 0.52 (34) 
JWH-122 0.7 (36) 1.2 (36) 
JWH-073 8.9 (35,37) 27 (35), 38 
(37) 
JWH-018 9 (35) 2.9 (35) 
CP47,497 9.54 (38)  
JWH-250 11(39) 33(39) 
Δ9-THC 39.5 (34) 40 (34) 
JWH-015 383 (34), 
164(35) 
13.8 (34,35) 
Table 3. Receptro affinities for both cannabinoid receptors for some common cannabimimetics. 
 
daily basis for about 8 months. While the 
patient initially used only 1g of product 
every day, the decreasing effect 
experienced made him increase the dose up 
to 3g daily. Both physical (sweating, 
tremor, insomnia, nausea, etc.) as 
psychological (depression, desperation, 
desire for ‘Spice Gold’) effects were 
observed the first days of treatment in 
hospital (40). In another paper, psychosis 
was diagnosed in ten patients after 
smoking herbal blends containing synthetic 
cannabinoids, which lasted months after 
the final use (41). 
 Recently, compound specific data 
related to harm assessment have been 
included in the European Database on New 
Drugs (EDND). For two compounds, 
chronic physical damage after use is 
mentioned. It is related to learning 
difficulties and cognitive ailment for HU-
210 and JWH-018, respectively. Moreover, 
for both compounds physical dependence 
(withdrawal symptoms) was reported, 
together with psychological dependence 
for JWH-018 and JWH-122 (11).  
 Predicting the possible effects of a 
particular herbal blend, is almost 
impossible. It was shown that the content 
of these packages varies significantly and 
is often not in accordance with the 
indications on the package. Toxicological 
data on the used plant material are not 
available, and then again, mostly the 
indications on the packages with regards to 
the herbal material are not reliable (9). 
Concerning the added synthetic 
cannabinoids, it was shown that 
concentrations can vary (5) and that some 
blends may contain two or more active 
compounds (42). Although research 
showed that the used chemicals are of high 
purity (43), the presence of impurities with 
unknown toxicity cannot be ruled out. In 
that way, it is not possible to estimate the 
impact when smoking a few grams of a 
given mixture. In general, the observed 
effects are very diverse and highly 
dependent on the type of herbal blend or 
synthetic cannabinoid(s) used. Most 
described psychoactive effects are: 
alterations in mood (from euphoria to 
anxiety) (5), hallucinations, agitated 
behavior and hyperreflexia (16). Medical 
investigation showed symptoms like 
increased pulse rates (6) and blood 
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pressure, flushed skin, dilated pupils and 
nausea (16). It was reported that the major 
psychotropic and physical effects 
disappear after 6h to 8h (5,6). 
 Together with the fact that these 
cannabimimetics have stronger affinities 
for the cannabinoid receptors compared to 
THC, it is not unlikely that overdosing 
would lead to life-threatening 
intoxications. This is confirmed in case 
studies (44) and reflected in the increasing 
statistics of Poison Control Centers in the 
US: in 2011 there were reports of over 
4000 synthetic marijuana exposures in a 
period of 8 months, which is an increase of 
52% compared to 2010 (45). 
 
DETECTION OF SYNTHETIC 
CANNABINOIDS ABUSE  
 
 In the past, several screening 
procedures – both via immunological and 
chromatographic techniques – have been 
developed to screen for the use of products 
from Cannabis sativa in different matrices 
(18,46–49). The abuse of the growing 
group of cannabimimetics, synthesized 
over the last years, however, cannot be 
detected with these existing methods.  
 For the identification of spiked 
substances in the herbal material in 
particular, a more or less standard strategy 
is used. The herbal material is extracted 
and subsequently analyzed by means of a 
chromatographic technique mostly 
combined with mass spectrometric 
detection (50). Next, the outcome is 
compared with databases containing the 
already known synthetic cannabinoids 
(51). If it turns out to be an unknown 
compound, the structure is elucidated by 
using high resolution mass spectrometry 
(HRMS) or NMR (Nuclear Magnetic 
Resonance) technology (52–54). 
 When it comes to detection in the 
human body, different approaches can be 
used depending on the type of biological 
sample available. In serum or whole blood, 
both the unchanged target compound and 
its metabolites are present and can be 
extracted and analyzed by means of liquid 
chromatography (LC) (55,56). The 
methods developed up till now mostly 
target the parent compounds, since this 
eliminates the need for the time-consuming 
search for metabolites and allows the quick 
update of the method after the release of a 
new compound in the future (57,58). For 
oral fluid testing, detection of this parent 
compound is possible, even via direct 
injection on the LC system (59). However, 
it should be noted that detection in the 
latter matrix is limited to a few hours after 
consumption (60). 
 If urine is the matrix of choice, 
knowledge on the metabolisation is 
essential, since no unchanged parent 
compound is found to be excreted. To 
detect these metabolites, an enzymatic 
hydrolysis is usually performed, followed 
by an extraction and analysis by means of 
liquid chromatography coupled to mass 
spectrometry (LC-MS) (61). For JWH-018 
it was found that monohydroxylated (31) 
and carboxy metabolites (28,62) are 
excreted in the highest concentrations, 
which makes these the metabolites of 
choice to implement in routine screening 
methods. Similar results are found for 
other indole-based cannabimimetics 
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(26,29,63,64). Based upon these findings, 
chromatographic methods are developed 
and validated to screen for synthetic 
cannabinoid metabolites in urine (65,66). 
Also commercial tests for synthetic 
cannabinoids became available, promising 
a detection window of 72 h after a single 
use. Peer-reviewed data on detection times 
- although rare - indicate similar ranges 
(30,67). No information is available on the 
accumulation in the body for chronic users. 
However, in those cases detection in urine 
would be possible up to 3 weeks (67).  
 Immunochemical-based detection 
methods have the advantage of being 
cheaper and faster than the 
chromatographic procedures referred to 
above, but the development and 
implementation was long in coming. 
Indeed, developing such immunoassays is 
a challenging task given the great 
structural variety between the compounds 
of the cannabimimetics family. Only 
recently, the first screening method, using 
enzyme linked immunosorbent assays 
(ELISA) for the detection of metabolites of 
the naphthoylindole group in urine, has 
been described in literature (68). 
Gradually, also commercial kits for high-
throughput screening of synthetic 
cannabinoids have become available 
(69,70). For any positive outcome 
however, a confirmatory analysis by means 
of the more selective chromatographic 
techniques remains essential. 
 It should be noted that correct 
identification of these products remains a 
difficult task since the availability of 
reference material is lagging behind on the 
rapid release of new products on the 
market (6). The latter makes it also 
difficult to keep screening methods up to 
date, since the existing methods are not 
able to detect non-target (i.e. currently 
unknown) compounds. To close this gap, 
an open screening approach whereby the 
method is capable of detecting a class of 
cannabinoids in a non-targeted way could 
be a solution. 
 
PERSPECTIVES - CONCLUSIONS 
 
 Despite the increasing number of 
actions taken by governments and other 
(inter)national institutions, the ‘Spice’ 
issue is still expanding. The list of 
synthetic cannabinoids detected continues 
to grow and the statistics on 
hospitalizations due to the use of these 
herbal blends are following the same trend.  
Although effective interventions of the 
authorities are necessary to tackle these 
problems, strict legislation also has a 
downside. The total ban on these products 
takes away the opportunity to investigate 
the therapeutic properties. Taking into 
account the successful use of plant derived 
cannabis in medicine, there is demand to 
provide the possibility to do research that 
leads towards the medicinal use of these 
synthetic analogues (71). 
 It is clear that further research in 
this field is necessary. When it comes to 
pharmacodynamics, so far only the 
properties of the parent compound are 
investigated. However, recent data show 
that also the formed metabolites remain 
active in the human body by binding to 
both cannabinoid receptors (72). 
 For routine testing, methods should 
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be developed to improve detection in 
different biological matrices. Given the 
rapidly growing number of products 
appearing on the market, an open-
screening approach could be a big step 
forward. When routine screening becomes 
more common, there will be a need for 
uniform regulations taking also into 
account the problem of passive inhalation, 
as known for THC smoke. 
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